JSPR Stock Analysis: Buy, Sell, or Hold?
JSPR - Jasper Therapeutics, Inc. Common Stock
$0.60
-0.03 (-4.32%)
▼
5d:
-13.18%
30d:
+40.74%
90d:
-35.2%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
8d
Get Alerted When JSPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JSPR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: JSPR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: JSPR is currently trading at $0.60, which is considered fair relative to its 30-day fair value range of $0.47 to $0.74.
Technical Outlook: Technically, JSPR is in a strong downtrend. Immediate support is located at $0.55, while resistance sits at $0.88. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.17 (+1355.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JSPR is in a strong downtrend. Immediate support is located at $0.55, while resistance sits at $0.88. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.17 (+1355.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.47 -
$0.74
Company Quality Score
45/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
55.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 1355.0% below Wall St target ($9.17)
- CAUTION: 5-day price weakness (-13.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.47 -
$0.74
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.36
(59.4%)
Support & Resistance Levels
Support Level
$0.55
Resistance Level
$0.88
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.25
Wall Street Target
$9.17
(+1355.0%)
Share & Embed Analysis
Last updated: August 03, 2026 1:47 PM ET
Data refreshes hourly during market hours. Next update: 2:47 PM
Data refreshes hourly during market hours. Next update: 2:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JSPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
